Latest News

CHAIN Celebrates Feasibility Study Success at Collaboration Nation

CHAIN Biotech has successfully completed a feasibility study into altering bacterial metabolism to produce novel chemicals. The four-month project was funded by Innovate UK, the UK’s innovation agency, and performed at Imperial College, London.

In nature, some chemicals exist in two forms which are mirror images of each other, like our left and right hands – the S and R forms. Chemical synthesis often results in a racemic mixture which contains both forms. However, one form may have a detrimental effect while the other has a positive one. In its project, CHAIN has succeeded in producing and analysing a right-handed R-form of a chemical from a bacterial host.

Presenting key findings at the Innovate UK Collaboration Nation event in London last Wednesday, CHAIN’s Business Development Manager, Mr Ben Bradley, said “During this project we validated our ‘chiral switch’ technology which allows us to change the stereochemistry of key intracellular metabolites.  We can now produce chemicals in the R-form, rather than the native S-form, that is required for certain nutraceutical and pharmaceutical applications.’’

Mr Bradley explained that this project forms a key component of CHAIN’s Anaerobic Fermentation Technology Platform. The demonstration of chiral-switch technology and novel analysis is leading the company to seek new partnerships in the fields of modelling, protein engineering and downstream processing to help build on the project’s success.

CHAIN would like to thank Innovate UK for supporting this work and also our hosts at Imperial College, SynbiCITE.

Related News

CHAIN Awarded £0.5M Grant Funding to Develop Healthcare Platform

CHAIN Biotech has been awarded £0.5M grant funding from Innovate UK, the UK’s innovation...

CHAIN Appoints New Board Members

CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald...

CHAIN Finalists in Biotechnology Awards

CHAIN Biotechnology is proud to announce that it is a finalist in two competitions...

CHAIN Celebrates Successful ‘Chiral Chemical Synthesis in Clostridia’ Study

LONDON, UK, 10 AUGUST 2016 -- CHAIN Biotechnology Ltd has successfully completed a 12-month...

omega 3 nutritional supplements
CHAIN Obtains Grant Funding For Collaborative Projects

June 11, 2016 – London, UK. CHAIN Biotechnology Ltd has won grant funding for...

CHAIN new employees clostridium modular vectors omega 3
CHAIN Welcomes New Starters

CHAIN has hired two new world class scientific team members to expand its role...

CHAIN Secures Seed Funding and Appoints New Board Members

London, UK, 23 December, 2015 CHAIN has successfully completed its first round of seed funding...

CHAIN Wins Business Interaction Voucher for clostridia strain development
CHAIN Wins Business Interaction Voucher with University of Nottingham

CHAIN Biotechnology has been awarded a £5,000 Business Interaction Voucher in partnership with the...

CHAIN launches a new grant funded research project

CHAIN has been awarded £180K from InnovateUK for a project focused on the production...

CHAIN wins award and launches new website

Award winning CHAIN Biotech launches its new website, funded by a prize voucher from...

CHAIN joins University of Nottingham Synthetic Biology Research Centre

CHAIN Biotechnology Ltd is proud to announce a new collaboration with Professor Nigel Minton’s...

CHAIN hires Research Manager

CHAIN Biotechnology Ltd welcomes Dr Dana Heldt. Dana is an experienced strain development scientist...